- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02711605
UltraShape Device for Non-Invasive Fat Reduction in the Male Breast (Pseudogynecomastia)
Clinical Evaluation of the UltraShape Device for Non-Invasive Fat Reduction in the Male Breast (Pseudogynecomastia)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Up to 40 adult male volunteers, who suffer from Pseudogynecomastia, and seek noninvasive breast fat reduction will be enrolled at up to three investigational sites. Eligible subject will be divided into one of the two treatment arms: Arm 1: Subjects will be treated on one side of the breast, while the opposite side will serve as control - Up to 20 subjects; Arm 2: Subjects will be treated on both sides of the breast - Up to 20 subjects. Subjects will receive 3 bi-weekly treatments (at 2-week intervals) with the UltraShape device.
Subjects will return for 3 follow-up visits post last treatment (Tx.3): four weeks follow-up (4wk FU), eight weeks follow-up (8wk FU) and 12 weeks follow-up (12wk FU) for total expected study duration of 16 weeks.
Study Type
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Signed informed consent to participate in the study
- Male subjects, 18 -70 years of age at the time of enrollment
- BMI interval: BMI ≥ 22 and ≤30 (normal to overweight, but not obese)
- Fat thickness of at least 1.5 cm in the treated area (breast) as measured by calibrated caliper.
- Subject has clearly visible, palpable, excess fatty tissue in their breast area, and minimal fibrous tissue.
- Subject agrees to maintain their weight (i.e., within 3% weight change) by not making any major changes in their diet or lifestyle during the course of the study.
- General good health confirmed by medical history and skin examination of the treated area.
- Willing to follow the treatment and follow-up schedule and post-treatment care instructions.
- Willing to have photographs and images taken of the treated areas to be used, de-identified in evaluations, publications and presentations.
Exclusion Criteria:
- History of hypertension, ischemic heart disease, valvular heart disease, congestive heart failure, pacemaker/defibrillator.
- Known hyperlipidemia, diabetes mellitus, hepatitis, liver disease, HIV positive status, blood coagulopathy or excessive bleeding, autoimmune or connective tissue disease.
- Having or undergoing any form of treatment for active cancer, or having a history of skin cancer or any other cancer in the areas to be treated, including presence of malignant or pre-malignant pigmented lesions.
- Having any active electrical implant anywhere in the body, such as a pacemaker or an internal defibrillator.
- Having a permanent implant in the treated area, such as metal plates or an injected chemical substance such as silicone.
- Having undergone any other surgery in the treated areas within 12 months of treatment or during the study, including liposuction.
- Previous body contouring procedures in the treatment area within 12 months.
- History of skin disease in the treatment area, known tendency to form keloids or poor wound healing.
- Suffering from significant skin conditions in the treated areas or inflammatory skin conditions, including, but not limited to, open lacerations or abrasions and active cold sores or herpes sores prior to treatment (duration of resolution as per the Investigator's discretion) or during the treatment course.
- Skin lesions in the treatment area other than simple nevi on physical examination (e.g., atypical nevus, tattoo, abrasions) including depressed scars in the treatment area.
- Very poor skin quality (i.e., severe laxity) according to the investigator decision.
- Obesity (BMI >30).
- Unstable weight within the last 6 months (i.e., 3% weight change in the prior six months).
- Inability to comply with circumference measurement procedure (e.g., inability to hold breath for the required duration).
- Fat thickness lower than 2.5 cm after strapping at the treated area.
- Participation in another clinical study involving same anatomical areas within the last 6 months (or 30 days in case different anatomical areas were treated in previous trial/s).
- As per the Investigator's discretion, any physical or mental condition which might make it unsafe for the subject to participate in this study.
- Personal history of previous breast malignancy.
- Subject is taking any medication which could cause abnormal breast enlargement - including but not limited to: digoxin, furosemide, gonadotropins, clomiphene, phenytoin, and exogenous testosterone, ketoconazole, metronidazole, alkylating agents, cisplatin, spironolactone, cimetidine, flutamide, finasteride, etomidate, isonicotinic acid hydrazide, methyldopa, busulfan, tricyclic antidepressants, diazepam, penicillamine, omeprazole, phenothiazines, calcium channel blockers, angiotensin-converting enzyme (ACE) inhibitors.
- Subject has history of the following medical conditions: Klinefelter syndrome, Congenital anorchia, Testicular trauma, Testicular torsion, Viral orchitis, Kallmann syndrome , Pituitary tumors, Malignancies that increase the serum level of hCG (eg, large cell lung cancer, gastric carcinoma, renal cell carcinoma, hepatoma), Renal failure, Hyperthyroidism, Malnutrition, Androgen insensitivity syndrome, Five-alpha-reductase deficiency syndrome.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Unilateral UltraShape treatment
One side of the chest (left or right breast) will be treated with the UltraShape focused ultrasound device, while the opposite will serve as an untreated control.
|
3 biweekly focused ultrasound treatments to the male chest with UltraShape.
Other Names:
|
Experimental: Bilateral UltraShape treatment
Both sides of the chest (right and left breasts) will be treated with the UltraShape focused ultrasound device.
|
3 biweekly focused ultrasound treatments to the male chest with UltraShape.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Reduction in breast fat thickness after 3 treatments compared to baseline
Time Frame: 12 weeks after 3rd treatment (16 weeks)
|
Average reduction in breast fat thickness after 3 treatments compared to baseline, as measured by ultrasound imaging
|
12 weeks after 3rd treatment (16 weeks)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Reduction in breast fat thickness on treated side compared to control side
Time Frame: 12 weeks after 3rd treatment (16 weeks)
|
Average reduction in breast fat thickness on treated side compared to control side, as measured by ultrasound imaging (Arm 1 only)
|
12 weeks after 3rd treatment (16 weeks)
|
Reduction in breast/chest circumference after 3 treatments compared to baseline
Time Frame: At 4-week, 8-week and 12-week follow-ups
|
Average reduction in breast/chest circumference after 3 treatments compared to baseline, as measured by measuring tape (Arm 2 only)
|
At 4-week, 8-week and 12-week follow-ups
|
Reduction in breast fat thickness compared to baseline
Time Frame: At 4-week, 8-week and 12-week follow-ups
|
Average reduction in breast fat thickness compared to baseline, as measured by skin caliper
|
At 4-week, 8-week and 12-week follow-ups
|
Reduction in breast fat thickness on treated side compared to control side
Time Frame: At 4-week, 8-week and 12-week follow-ups
|
Average reduction in breast fat thickness on treated side compared to control side, as measured by skin caliper (Arm 1 only)
|
At 4-week, 8-week and 12-week follow-ups
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with adverse events
Time Frame: through study duration up to 1 year
|
The number of adverse events, severity, intervention and outcome, as reported on adverse event forms
|
through study duration up to 1 year
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Shlomit Mann, MA, Syneron Medical
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- DHF21271
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gynecomastia
-
Zagazig UniversityCompletedGynecomastia, AdolescentEgypt
-
Apyx MedicalCompletedGynecomastiaUnited States
-
Sohag UniversityActive, not recruiting
-
Dermatology, Laser & Vein Specialists of the CarolinasUnknownGynecomastiaUnited States
-
Lawson Health Research InstituteNot yet recruitingBreast Cancer | Gynecomastia | Transgenderism | Breast Asymmetry
-
Al-Kindy College of MedicineCompletedGynecomastia | Surgical Incision
-
Franklin Health ResearchRecruiting
-
Groupe Hospitalier Paris Saint JosephCompleted
Clinical Trials on UltraShape focused ultrasound device
-
Syneron MedicalWithdrawn
-
Sunnybrook Health Sciences CentreTerry Fox Research InstituteRecruiting
-
Sunnybrook Health Sciences CentreRecruiting
-
Sunnybrook Health Sciences CentreTerry Fox Research InstituteNot yet recruiting
-
Northwestern UniversityActive, not recruiting
-
Nader SanaiInSightec; SonALAsense, Inc.; Barrow Neurological Institute; Ivy Brain Tumor CenterRecruitingHigh Grade GliomaUnited States
-
University of California, Los AngelesTiny Blue Dot Foundation; The Dana FoundationTerminatedBrain Injuries | Consciousness DisordersUnited States
-
Oxford University Hospitals NHS TrustTheraclionTerminatedParathyroid AdenomasUnited Kingdom
-
Shufang ChangRecruitingCervical Intraepithelial NeoplasiaChina
-
University of California, Los AngelesNational Institute on Aging (NIA)RecruitingMild Cognitive Impairment | Deep Brain Stimulation | Amnestic Mild Cognitive Disorder | Mild Alzheimer's DiseaseUnited States